GENE ONLINE|News &
Opinion
Blog

2021-01-12| Asia-PacificCOVID-19

Philippines Signs Second Vaccine Deal to Procure 30 Million Doses of Novavax’s Covovax

by Tyler Chen
Share To

The Philippines government has signed a second vaccine deal to procure 30 million doses of Covovax, the COVID-19 vaccine developed by Novavax. The candidate is developed by the Serum Institute of India (SII), one of the largest vaccine makers. The vaccine will be available in the 3rd quarter of 2021.

 

No Vaccines Approvals Yet

Phillippine aims to vaccinate 70% of the population. To achieve that, the Philippines needs to acquire at least 148 million doses.

According to Faberco Life Sciences Medical Director Dr. Luningning Villa: “The vaccine will be used to vaccinate 15 million vulnerable and poor Filipinos. The vaccine is stable at 2°C to 8°C, the standard temperature that is within the existing cold chain system in the Philippines, thus allowing its distribution to the remotest barangays.”

For now, three vaccine providers, Pfizer, AstraZeneca, and Russia’s Gamaleya, have submitted applications of emergency use authorization for vaccine in Phillippine, but none have been approved.

AstraZeneca is the first vaccine manufacturer that has struck up a deal with the Philippines government. At the end of November, AstraZeneca promised 2.6 million vaccines that will arrive by May, June. Carlito Galvez, a former military general in charge of the Philippines’ strategy to fight the coronavirus, revealed that the Philippines private sector is also attempting to obtain 1 million doses.

The Philippines government is currently negotiating with 7 manufacturers for possible vaccine deals to accomplish the goal.

 

Entering Phase 3 Clinical Trials

Covovax is made of a recombinant coronavirus spike protein nanoparticle and a Novavax-patented Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax collaborated with the Indian Council of Medical Research (ICMR) for conducting clinical trials.

The early stage of the Covovax trial conducted in Australia, South Africa, and India included 50,000 subjects with different geographies, ages, and subjects that are racial and ethnic minorities to ensure the data is sturdy enough while the phase 3 trials are currently run in the UK, U.S., and Mexico.

Related Articles: Novavax’s COVID-19 Vaccine is Safe and Immunogenic in Early Trial

References
  1. https://pia.gov.ph/news/articles/1063484
  2. https://www.bloomberg.com/news/articles/2020-11-27/philippines-signs-deal-with-astrazeneca-for-2-6-million-doses
  3. https://www.seruminstitute.com/news_sii_icmr_partnership.php

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
CDC Warns Of “Tripledemic” Winter Amid Rising Flu And RSV Cases
2022-11-14
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
AstraZeneca’s COVID-19 Vaccine Finally Wins Full Authorization in the European Union
2022-11-01
LATEST
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
Novartis’ Pluvicto Continues Winning Streak In Prostate Cancer Indication
2022-12-07
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
European Commission Continues Fight with Illumina and Orders Grail Acquisition Divestment
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!